福巴替尼的药物相互作用是什么？

(futibatinib) was developed by Taiho Oncology, a subsidiary of Japan's Dapeng Pharmaceuticals, and was approved by the US FDA for marketing on September 30, 2022. The trade name is Lytgobi. It is used to treat adult patients with locally advanced or metastatic intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) gene fusion. However, when using forbatinib, you still need to pay attention to its effects when combined with other drugs. So, what are the drug interactions of forbatinib?

forbatinib

Forbatinib is an irreversibly covalently bound FGFR inhibitor, and other approved FGFR inhibitors are reversible ATP competitive inhibitors. This product is a tablet, 20 mg per day, once a day.

Forbatinib drug interactions

1. Effects of other drugs on forbatinib

Fortibatinib is a substrate of CYP3A and P-gp. Dual P-gp and Strong CYP3A Inhibitors Avoid coadministration of drugs with dual P-gp and strong CYP3A inhibitors with Lytgobi. Coadministration of dual P-gp and strong CYP3A inhibitor drugs with LYTGOBI may increase futibatinib exposure.

2. Effect of forbatinib on other drugs

Fortibatinib is an inhibitor of P-gp and BCRP. Consider more frequent monitoring for adverse reactions associated with concomitantly administered drugs that are sensitive substrates of P-gp or BCRP and reduce the dosage of these drugs according to their prescribing information. Fortibatinib may increase exposure to drugs that are P-gp or BCRP substrates.

Forbatinib usage and dosage for special populations

1. Pregnancy

Forbatinib administration to pregnant women can cause fetal harm or pregnancy termination, based on the results of an animal study and its mechanism of action.

2. Breastfeeding

Because forbatinib may cause serious adverse reactions in breastfed children, advise women not to breastfeed during treatment and for 1 week after the last dose.

3. Medication for the elderly

Of the 103 patients treated with forbatinib in study TAS-120-101, 22% were 65 years or older. Based on the available data, no overall differences in the safety or effectiveness of forbatinib were observed between patients aged 65 years and older and younger adult patients.

Recommended hot articles: